Shanghai Fosun Pharmaceutical (600196) H1 2025 earnings summary

Executive summary

• Revenue for H1 2025 was RMB 19,514 million, down 4.63% year-over-year, mainly due to VBP and centralized procurement; innovative drugs revenue grew 14.26% to over RMB 4,300 million.

• Net profit attributable to shareholders rose 38.96% year-over-year to RMB 1,702 million, driven by asset disposals including United Family Healthcare; net profit after one-off gains was RMB 961 million, down 23.39% year-over-year.

• Operating cash flow increased 11.90% year-over-year to RMB 2,134 million, reflecting supply chain and operational efficiency improvements.

• R&D investment reached RMB 2,584 million, with a focus on innovative drugs and system optimization, accounting for 13.24% of revenue.

• Significant product launches and regulatory approvals, including Luvometinib, Fovinaciclib, and Serplulimab in China and internationally.

Financial highlights

• Gross margin was 48.1%, slightly down from 48.9% in 1H24; selling and distribution expense ratio increased to 21.6%.

• Pharma segment revenue fell 5.29% year-over-year to RMB 13,901 million; segment profit rose 1.01% year-over-year to RMB 1,587 million.

• Med Tech segment revenue declined 5.51% year-over-year to RMB 1,955 million, but segment profit improved by RMB 73 million year-over-year.

• Healthcare Services segment revenue decreased 1.83% year-over-year to RMB 3,592 million; segment loss narrowed.

• Cash and bank balances stood at RMB 12,959 million; current ratio at 0.95, quick ratio at 0.77, and debt-to-asset ratio at 49.2%.

Outlook and guidance

• Continued transformation toward innovative drugs, high-value devices, and international expansion, with a robust pipeline.

• Ongoing investment in R&D, digitalization, and AI to drive future growth and operational efficiency.

• Strategic focus on oncology, hematology, immunology, and expansion into chronic and CNS diseases.

• Equity incentive plans and share repurchases to align interests and support long-term value creation.